Header Logo

Connection

JOSEPH JANKOVIC to Dopamine Agonists

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Dopamine Agonists.
JOSEPH JANKOVIC
Connection Strength
4.796
Dopamine Agonists
  1. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.885
  2. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.375
  3. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.276
  4. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007 Jun; 8(9):1329-35.
    View in: PubMed
    Score: 0.271
  5. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul; 73(4):682-9.
    View in: PubMed
    Score: 0.254
  6. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
    View in: PubMed
    Score: 0.215
  7. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003 Nov; 12(11):1803-20.
    View in: PubMed
    Score: 0.211
  8. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep; 17(5):1031-5.
    View in: PubMed
    Score: 0.195
  9. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26; 58(4 Suppl 1):S19-32.
    View in: PubMed
    Score: 0.188
  10. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001 Sep-Oct; 24(5):247-53.
    View in: PubMed
    Score: 0.182
  11. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
    View in: PubMed
    Score: 0.174
  12. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
    View in: PubMed
    Score: 0.174
  13. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):252-61.
    View in: PubMed
    Score: 0.170
  14. New and emerging therapies for Parkinson disease. Arch Neurol. 1999 Jul; 56(7):785-90.
    View in: PubMed
    Score: 0.156
  15. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
    View in: PubMed
    Score: 0.126
  16. Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
    View in: PubMed
    Score: 0.122
  17. Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015 Jun; 16(6):678-90.
    View in: PubMed
    Score: 0.116
  18. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
    View in: PubMed
    Score: 0.102
  19. Pain in Parkinson's disease. Mov Disord. 2012 Apr; 27(4):485-91.
    View in: PubMed
    Score: 0.091
  20. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011 Dec; 82(12):1300-3.
    View in: PubMed
    Score: 0.091
  21. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008 Jan; 7(1):9-11.
    View in: PubMed
    Score: 0.071
  22. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
    View in: PubMed
    Score: 0.066
  23. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005 Aug; 62(8):1290-5.
    View in: PubMed
    Score: 0.060
  24. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.047
  25. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.044
  26. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001 Mar; 114(3):227-34.
    View in: PubMed
    Score: 0.044
  27. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
    View in: PubMed
    Score: 0.041
  28. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999; 64(15):1275-85.
    View in: PubMed
    Score: 0.038
  29. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.